

SIFO feedback to roadmap

Feedback reference: F507628

Submitted on: 03 March 2020

Submitted by: maria grazia cattaneo

User type: Other

Organisation: SIFO Italian Society of Hospital Pharmacy

Organisation size: Micro (1 to 9 employees)

Country of origin: Italy

Initiative: [Europe's Beating Cancer Plan](#)

We wish to thank EU for the opportunity to be able to send a contribution to the discussion. We agree on the roadmap. Our scientific society SIFO, the Italian Society of Hospital Pharmacy and Pharmaceutical Services of Healthcare Companies, is currently engaged on several fronts regarding the cancer emergency: safety in places of care for patients and operators exposed to dangerous drugs including cytotoxic; safety of galenic drugs prepared at Antineoplastic Drug Units, according to the best European and national standards; research and development of innovative drugs; promotion of national cancer networks; preparation of local therapy courses in a multidisciplinary and multi-professional group; promotion of adherence to therapies; pharmacovigilance; data collection in national registers; training activities for operators and patients; reconciliation activities to support specialist doctors. In this regard, the European Commission is requested to: - promotes strong monitoring so that the national and international legislative requirements in force for the protection of any person present in the structures are able to guarantee safety and are applied both in healthcare structures and at the patient's home.

There are in fact still structures in which antineoplastic drugs are prepared in the oncology wards, despite the current legislation requiring maximum safety for this activity; -promote training and information exchanges of clinical, pharmaceutical and management content between member states; - promote the exchange of good quality and safety practices; -promote quality certification of care management systems; - promote a sharing of resources and therefore promote a European network that compares itself on the data collected and shared. -promote the Units of oncological pathology so that they really work and consist of all the professions and specialties involved. -The explanation of possible adverse events and drug interactions must be given to the patient and family members by a clinical pharmacist, who will follow up the patient during the entire treatment cycle. -The pharmacist must be an active part in the ward, next to the patient. -The patient must be really at the center of the management and organizational strategies of Health Managers.